Biotech News

Innate Pharma announces conference call and webcast

Innate Pharma (IPHA)Innate PharmaConference / presentation

Fri, 08/14/2026 - 11:30

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT.

Participants during the call will be:

Jonathan Dickinson, Chief Executive Officer

Yannis Morel, Executive Vice President, Chief Operating Officer

Frédéric Lombard, Senior Vice President, Chief Financial Officer

Stéphanie Cornen, Vice President, Investor Relations, Communication

Event Details The live webcast will be available at the following link: https://events.q4inc.com/attendee/322508798

Participants may also join via telephone using the following registration link: https://events.q4inc.com/analyst/322508798?pwd=Cl4ian4X

This information is also available on the Investors section of the Innate Pharma website, www.innate-pharma.com . A replay of the webcast will be available on the Company website.

Related news

IPHAInnate Pharma2026-07-22 11:17 EST

Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference

IPHAInnate Pharma2026-07-20 14:53 EST

Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Innate Pharma

Innate Immunity Oncology Company Innate Pharma develops antibodies and antibody-drug conjugates that engage innate and adaptive immunity against cancer. Lacutamab Lacutamab targets KIR3DL2 and is being developed for cutaneous T-cell lymphoma. ADC and Partnered Pipeline IPH4502 is a Nectin-4 ADC, while partnered programs include...

Recent company news

Stock data

Close
2.26 USD
Market cap
170.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States